accountin the United States in March, following earlier delays, where Forest Laboratories has the marketing rights. In Europe, Merck & Co has the marketing rights. Nycomed has been the subject of much speculation about a sale or an IPO, with the Wall Street...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Takeda in talks with Nycomed, deal may be $14.2 bn
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account